Inhibition of influenza a virus replication by antagonism of a PI3K-AKT-mTOR pathway member identified by gene-trap insertional mutagenesis

Antiviral Chemistry and Chemotherapy

Volumn 22, Issue 5, 2012, Pages 205-215

  Murray, James L ^a   McDonald, Natalie J ^a   Sheng, Jinsong ^b   Shaw, Michael W ^c   Hodge, Thomas W ^a   Rubin, Donald H ^b,d   O'Brien, William A ^a,e,f   Smee, Donald F ^g  

^a Zirus Inc   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e University of Texas Medical Branch School of Medicine   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UTAH STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; OSELTAMIVIR; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; RIBAVIRIN; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; COWPOX VIRUS; DENGUE; DENGUE VIRUS 2; DRUG APPROVAL; FEMALE; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; GENE INACTIVATION; GENE INSERTION; GENE SILENCING; GENETIC SCREENING; IN VITRO STUDY; INFLUENZA A (H1N1); INFLUENZA A (H5N1); INFLUENZA VIRUS A; LETHALITY; LUNG HEMORRHAGE; LUNG WEIGHT; MORTALITY; MOUSE; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RHINOVIRUS; RNA INTERFERENCE; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MUTAGENESIS, INSERTIONAL; OSELTAMIVIR; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBAVIRIN; RNA INTERFERENCE; SIROLIMUS; TOR SERINE-THREONINE KINASES; VIRUS REPLICATION;

EID: 84863113748     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2080     Document Type: Article

References (44)

1. Zakay-Rones Z. Human influenza vaccines and assessment of immunogenicity. Expert Rev Vaccines 2010; 9:1423-1439.
2. Greenberg HB, Piedra PA. Immunization against viral respiratory disease: a review. Pediatr Infect Dis J 2004; 23:S254-S261.
3. Centers for Disease Control and Prevention. Oseltamivir-resistant 2009 pandemic infuenza A (H1N1) virus infection in two summer campers receiving prophylaxis - North Carolina, 2009. MMWR Morb Mortal Wkly Rep 2009; 58:969-972.
4. Centers for Disease Control and Prevention. 2009 pandemic infuenza A (H1N1) virus infections - Chicago, Illinois, April-July 2009. MMWR Morb Mortal Wkly Rep 2009; 58:913-918.
5. Pizzorno A, Abed Y, Boivin G. Influenza drug resistance. Semin Respir Crit Care Med 2011; 32:409-422.
6. Smith SM, Gums JG. Antivirals for influenza: strategies for use in pediatrics. Paediatr Drugs 2010; 12:285-299.
7. Betakova T, Nermut MV, Hay AJ. The NB protein is an integral component of the membrane of infuenza B virus. J Gen Virol 1996; 77:2689-2694.
8. Hauge SH, Dudman S, Borgen K, Lackenby A, Hungnes O. Oseltamivir-resistant infuenza viruses A (H1N1), Norway, 2007-08. Emerg Infect Dis 2009; 15:155-162.
9. Bloom JD, Gong LI, Baltimore D. Permissive secondary mutations enable the evolution of infuenza oseltamivir resistance. Science 2010; 328:1272-1275.
10. Rubin DH, Ruley HE. Cellular genetics of host susceptibility and resistance to virus infection. Crit Rev Eukaryot Gene Expr 2006; 16:155-170.
11. von Melchner H, Ruley HE. Identification of cellular promoters by using a retrovirus promoter trap. J Virol 1989; 63:3227-3233.
12. Murray JL, Mavrakis M, McDonald NJ, et al. Rab9 GTPase is required for replication of human immunodeficiency virus type 1, floviruses, and measles virus. J Virol 2005; 79:11742-11751.
13. Organ EL, Sheng J, Ruley HE, Rubin DH. Discovery of mammalian genes that participate in virus infection. BMC Cell Biol 2004; 5:41.
14. Sheng J, Organ EL, Hao C, et al. Mutations in the IGF-II pathway that confer resistance to lytic reovirus infection. BMC Cell Biol 2004; 5:32.
15. Ivie SE, Fennessey CM, Sheng J, Rubin DH, McClain MS. Gene-trap mutagenesis identifies mammalian genes contributing to intoxication by Clostridium perfringens epsilon-toxin. PLoS ONE 2011; 6:e17787.
16. Buchkovich NJ, Yu Y, Zampieri CA, Alwine JC. The TORrid affairs of viruses: effects of mammalian DNA viruses on the PI3K-Akt-mTOR signalling pathway. Nat Rev Microbiol 2008; 6:266-275.
17. Cooray S. The pivotal role of phosphatidylinositol 3-kinase-Akt signal transduction in virus survival. J Gen Virol 2004; 85:1065-1076.
18. Ehrhardt C, Marjuki H, Wolff T, et al. Bivalent role of the phosphatidylinositol-3-kinase (PI3K) during infuenza virus infection and host cell defence. Cell Microbiol 2006; 8:1336-1348.
19. Ehrhardt C, Wolff T, Pleschka S, et al. Influenza A virus NS1 protein activates the PI3K/Akt pathway to mediate antiapoptotic signaling responses. J Virol 2007; 81:3058-3067.
20. Hale BG, Jackson D, Chen YH, Lamb RA, Randall RE. Influenza A virus NS1 protein binds p85beta and activates phosphatidylinositol-3-kinase signaling. Proc Natl Acad Sci U S A 2006; 103:14194-14199.
21. Shin YK, Li Y, Liu Q, et al. SH3 binding motif 1 in influenza A virus NS1 protein is essential for PI3K/Akt signaling pathway activation. J Virol 2007; 81:12730-12739.
22. Shin YK, Liu Q, Tikoo SK, Babiuk LA, Zhou Y. Effect of the phosphatidylinositol 3-kinase/Akt pathway on infuenza A virus propagation. J Gen Virol 2007; 88:942-950.
23. Shin YK, Liu Q, Tikoo SK, Babiuk LA, Zhou Y. Influenza A virus NS1 protein activates the phosphatidylinositol 3-kinase (PI3K)/Akt pathway by direct interaction with the p85 subunit of PI3K. J Gen Virol 2007; 88:13-18.
24. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997; 278:687-689.
25. Hicks GG, Shi EG, Li XM, et al. Functional genomics in mice by tagged sequence mutagenesis. Nat Genet 1997; 16:338-344.
26. Sidwell RW, Smee D F, Huffman JH, et al. In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RJW-270201. Antimicrob Agents Chemother 2001; 45:749-757.
27. Huynh H, Chow KH, Soo KC, et al. RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. J Cell Mol Med 2009; 13:1371-1380.
28. LaMontagne K, Littlewood-Evans A, Schnell C, et al. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res 2006; 66:221-231.
29. Majewski M, Korecka M, Joergensen J, et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation 2003; 75:1710-1717.
30. Sidwell RW, Barnard DL, Day CW, et al. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob Agents Chemother 2007; 51:845-851.
31. Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 1938; 27:493-497.
32. Smee DF, Hurst BL, Wong MH, Bailey KW, Morrey JD. Effects of double combinations of amantadine, oseltamivir, and ribavirin on infuenza A (H5N1) virus infections in cell culture and in mice. Antimicrob Agents Chemother 2009; 53:2120-2128.
33. Voss MH, Molina AM, Motzer RJ. mTOR inhibitors in advanced renal cell carcinoma. Hematol Oncol Clin North Am 2011; 25:835-852.
34. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349:847-858.
35. Vítko S, Margreiter R, Weimar W, et al. Everolimus (Certican) 12-month safety and effcacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 2004; 78:1532-1540.
36. Hill JA, Hummel M, Starling RC, et al. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus. Transplantation 2007; 84:1436-1442.
37. Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 2006; 81:1234-1248.
38. Hofer A, Nichols T, Grant S, et al. Study of the PDK1/AKT signaling pathway using selective PDK1 inhibitors, HCS, and enhanced biochemical assays. Anal Biochem 2011; 414:179-186.
39. Bai X, Ma D, Liu A, et al. Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38. Science 2007; 318:977-980.
40. Sato T, Nakashima A, Guo L, Tamanoi F. Specifc activation of mTORC1 by Rheb G-protein in vitro involves enhanced recruitment of its substrate protein. J Biol Chem 2009; 284:12783-12791.
41. Wang X, Fonseca BD, Tang H, et al. Re-evaluating the roles of proposed modulators of mammalian target of rapamycin complex 1 (mTORC1) signaling. J Biol Chem 2008; 283:30482-30492.
42. Okamoto T, Nishimura Y, Ichimura T, et al. Hepatitis C virus RNA replication is regulated by FKBP8 and Hsp90. EMBO J 2006; 25:5015-5025.
43. Okamoto T, Omori H, Kaname Y, et al. A single-amino-acid mutation in hepatitis C virus NS5A disrupting FKBP8 interaction impairs viral replication. J Virol 2008; 82:3480-3489.
44. Wang J, Tong W, Zhang X, et al. Hepatitis C virus non-structural protein NS5A interacts with FKBP38 and inhibits apoptosis in Huh7 hepatoma cells. FEBS Lett 2006; 580:4392-4400.